Bonnie K Harrington, Esther Wheeler, Kasey Hornbuckle, Arwa Y Shana'ah, Youssef Youssef, Lisa Smith, Quais Hassan, Brett Klamer, Xiaoli Zhang, Meixiao Long, Robert A Baiocchi, Kami Maddocks, Amy J Johnson, John C Byrd, Lapo Alinari
Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy for which novel therapeutics with improved efficacy are greatly needed. To provide support for clinical immune checkpoint blockade, we comprehensively evaluated the expression of therapeutically targetable immune checkpoint molecules on primary MCL cells. MCL cells showed constitutive expression of Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1), variable CD200, absent PD-L2, Lymphocyte Activation Gene 3 (LAG-3), and Cytotoxic T-cell Associated Protein 4 (CTLA-4)...
October 2019: Leukemia & Lymphoma